0001179110-13-011897.txt : 20130718 0001179110-13-011897.hdr.sgml : 20130718 20130718134702 ACCESSION NUMBER: 0001179110-13-011897 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130718 FILED AS OF DATE: 20130718 DATE AS OF CHANGE: 20130718 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Omthera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001477598 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263797738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 707 STATE ROAD CITY: NEW JERSEY STATE: NJ ZIP: 08540 BUSINESS PHONE: 908-741-4323 MAIL ADDRESS: STREET 1: 707 STATE ROAD CITY: NEW JERSEY STATE: NJ ZIP: 08540 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sofinnova Partners SAS CENTRAL INDEX KEY: 0001574139 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35869 FILM NUMBER: 13974545 BUSINESS ADDRESS: STREET 1: 17 RUE DE SERENE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33 1 53 05 41 13 MAIL ADDRESS: STREET 1: 17 RUE DE SERENE CITY: PARIS STATE: I0 ZIP: 75008 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SOFINNOVA CAPITAL VI FCPR CENTRAL INDEX KEY: 0001441261 STATE OF INCORPORATION: XX FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35869 FILM NUMBER: 13974546 BUSINESS ADDRESS: STREET 1: C/O SOFINNOVA PARTNERS STREET 2: 17 RUE DE SURENE CITY: PARIS STATE: XX ZIP: 75008 BUSINESS PHONE: 33 1 53 054100 MAIL ADDRESS: STREET 1: C/O SOFINNOVA PARTNERS STREET 2: 17 RUE DE SURENE CITY: PARIS STATE: XX ZIP: 75008 4 1 edgar.xml FORM 4 - X0306 4 2013-07-18 1 0001477598 Omthera Pharmaceuticals, Inc. OMTH 0001441261 SOFINNOVA CAPITAL VI FCPR 17, RUE DE SERENE PARIS I0 75008 FRANCE 1 0 1 1 Director by Deputization 0001574139 Sofinnova Partners SAS 17, RUE DE SERENE PARIS I0 75008 FRANCE 1 0 1 1 Director by Deputization Common Stock 2013-07-18 4 D 0 7159317 D 0 D Graziano Seghezzi serves as a representative of Sofinnova VI FCPR and its affiliates on the board of directors of Omthera Pharmaceuticals, Inc. (the "Company") as a director by deputization. Pursuant to the Agreement and Plan of Merger by and among the Company, Zeneca, Inc. and KAFA Acquisition Corp., dated May 27, 2013, each share of the Company's common stock was exchanged for $12.70 in cash, without interest, less any applicable withholding taxes, plus one contractual contingent value right, which represents the right to receive contingent payments of up to approximately $4.70 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods. Sofinnova Partners SAS is the managing company of Sofinnova Capital VI FCPR and disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any. /s/Christian S. Schade, Attorney-in-Fact 2013-07-18 /s/Christian S. Schade, Attorney-in-Fact 2013-07-18